Year: 2019

 NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA) (THE “UNITED STATES”) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S UNDER THE SECURITIES ACT OF 1933, AS AMENDED) OR IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS DOCUMENT AND THE INVITATION FOR OFFERS. FURTHER CONDITIONS AND RESTRICTIONS APPLY.Luxembourg, 9 December 2019 – 10:15 CET – On 29 November 2019, ArcelorMittal (“ArcelorMittal” or the “Company”) announced the commencement of an invitation (subject to offer restrictions) to holders of the bonds (“Bondholders”) set forth in the table below (the “Bonds”)...

Der er i afdeling Othania Etisk Formuevækst KL under Investeringsforeningen Investin sket ændringer, hvorfor ajourført prospekt for Investeringsforeningen Investin offentliggøres.Ændringerne indebærer, at der under afsnittet “Samlede administrationsomkostninger” indføres følgende sætning:“… eksklusive afkastafhængigt honorar.”Således at det samlede afsnit nu lyder som følger:“I henhold til vedtægterne må de samlede administrationsomkostninger, herunder omkostninger til bestyrelse, administration, it, revision, tilsyn, markedsføring og depotselskab for hver afdeling ikke overstige 3,0% af den gennemsnitlige formueværdi af afdelingerne inden for et regnskabsår eksklusive afkastafhængige honorar.”Herudover er der foretaget almindelig årlig opdatering. Eventuelle henvendelser vedrørende denne meddelelse...

Selskabsmeddelelse nr. 33/2019 | 9. december 2019                                                                                  Den 1. oktober iværksatte Danske Andelskassers Bank A/S’ (”Banken”) et aktietilbagekøbsprogram. Aktietilbagekøbsprogrammet løber i perioden fra 1. oktober 2019 til 30. september 2020. I denne periode vil Banken opkøbe aktier for en maksimal værdi af 16.898.800 kroner, jf. selskabsmeddelelse nr. 18 af 24. september 2019.Efter ovenstående transaktioner ejer Banken i alt 1.349.976 egne aktier svarende til 0,7739 % af Bankens aktiekapital.Siden aktietilbagekøbsprogrammet blev iværksat den 1. oktober 2019, er der samlet købt 380.420 aktier for et samlet beløb på 2.551.235 kroner.Alle transaktioner er foretaget i ISIN DK0060299063.Vedhæftet filSelskabsmeddelelse_Aktietilbagekøb uge 49

Company Announcement No. 806On 11 November 2019, we initiated a share buyback programme, as described in Company Announcement No. 800 of 1 November 2019. According to the programme, the company will in the period from 11 November 2019 to 6 February 2020 purchase own shares up to a maximum value of DKK 2,500,000,000 and no more than 6,000,000 shares, corresponding to 2.55% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules.As at today, DSV Panalpina A/S holds a total of 5,478,254 shares of a nominal value of DKK 1 in DSV Panalpina A/S, corresponding to 2.33% of the total number of issued shares of...

Orion Corporation                        Press release                               9 December at 10.15 EETOrion has studied the effects of oral levosimendan on respiratory function in patients with ALS and presented biomarker and pharmacokinetic data from previous studies, a systematic literature review on pharmacological effects of levosimendan, and baseline characteristics and status update on the progression of REFALS phase 3 study at the 30th International Symposium on ALS/MND in Perth, Australia last week. https://www.orion.fi/en/rd/scientific-publications/Baseline characteristics and status update of REFALS: a phase 3 study comparing oral levosimendan to placebo in patients with ALS (poster CLT-18)The REFALS trial studying the effects of oral levosimendan on respiratory function in patients with ALS, completed enrolment in July...

ORION OYJ        LEHDISTÖTIEDOTE                                                  9.12.2019 klo 10.15Orion on tutkinut suun kautta annosteltavan levosimendaanin vaikutusta ALS-potilaiden hengitystoimintaan ja esitteli viime viikolla tuloksia aiemmista tutkimuksista sekä katsaukset potentiaalisista vaikutusmekanismeista ja meneillään olevan REFALS faasi 3 -tutkimuksen etenemisestä Perthissä, Australiassa järjestetyssä kansainvälisessä ALS/MND-symposiumissa (the 30th International Symposium on ALS/MND). https://www.orion.fi/en/rd/scientific-publications/REFALS-tutkimukseen rekrytoitujen potilaiden lähtötilanne ja tutkimuksen eteneminen: faasi 3 -vaiheen tutkimus levosimendaanin vaikutuksista ALS-potilailla (posteri CLT-18, englanniksi)REFALS-koe tutkii suun kautta annosteltavan levosimendaanin vaikutuksia ALS-potilaiden hengitystoimintaan....

VANCOUVER, British Columbia, Dec. 09, 2019 (GLOBE NEWSWIRE) — (TSX-V: NNO) (OTC-Nasdaq Intl Designation: NNOMF) (Frankfurt: LBMB).HighlightsRaw material suppliers accepted by Pulead;Engineering report available for partner review in Q1 2020Mr. Dan Blondal, CEO of Nano One Materials Corp., is pleased to report significant progress in Nano One’s ongoing joint development work with Pulead to develop, evaluate and optimize scaled production of lithium iron phosphate (LFP) cathode material using Nano One’s patented technology.“Nano One, working with a raw material sourcing expert in China, has identified raw material supply sources that meet both Nano One’s performance targets and Pulead’s specifications for impurities and cost,” said Mr. Blondal. “It is critical to cathode manufacturers that a sustainable supply of raw materials be...

SpareBank 1 SMN has on 6 December purchased 28,275 equity certificates at a price of NOK 97.62 per equity certificate for use in the group’s savings programme for employees.After this transaction the bank owns 28,900 ECC’s.Reference is made to the stock exchange notice dated 14 December 2018 for more information about the savings scheme. Reference is also made to the stock exchange notice of 29 March 2019, in which the authorization to buy back equity certificates is included in the resolution from SpareBank 1 SMN’s Supervisory Board.Trondheim, 6 December 2019                                                                                                    Contact person in SpareBank 1 SMN:Executive Vice President, Finance, Kjell Fordal, tel. 905 41 672This information is subject to the disclosure requirements pursuant to Section 5-12...

SpareBank 1 SMN har 6. desember kjøpt 28.275 egenkapitalbevis til kurs 97,62 kroner per egenkapitalbevis. Egenkapitalbevisene skal benyttes til videresalg til konsernets ansatte som deltar i spareordningen for 2019.Bankens beholdning av egne bevis etter denne transaksjonen er 28.900 bevis.Det henvises for øvrig til børsmelding av 14. desember 2018 for nærmere informasjon om spareordningen, og børsmelding av 29. mars 2019 der fullmakt til tilbakekjøp av egenkapitalbevis fremgår av vedtak fra representantskapsmøtet.Trondheim, 6. desember 2019                                                                                                    Kontaktperson i SpareBank 1 SMN:Finansdirektør Kjell Fordal, tlf. 905 41 672Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12

JOINT ANNUAL GENERAL MEETING 2019:APPROVAL OF THE FINANCIAL STATEMENTS FOR 2018-2019, RESULTING IN A TOTAL NET INCOME OF 77.9 MILLION EUROSNET DIVIDEND OF 1.35 EUROS PER SHARE  APPOINTMENT OF MARIE-YVONNE CHARLEMAGNE AS INDEPENDENT BOARD MEMBERAPPOINTMENT OF SÉBASTIEN VIDAL AS CHAIRMAN AND CEO OF VILMORIN & CIESIGNATURE OF A NEW AGREEMENT ON GENOME EDITING TECHNIQUESJOINT ANNUAL GENERAL MEETING 2019The Joint Annual General Meeting of Shareholders of Vilmorin & Cie met on Friday December 6, 2019 in Paris, under the chairmanship of Philippe AYMARD, Vilmorin & Cie’s Chairman and CEO.Almost 150 Shareholders had the opportunity to share their thoughts on the strategy and outlook of the Company, and to express themselves on the resolutions submitted for their approval.Approval of the financial statements for 2018-2019Vilmorin...